Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1238988 | 0.78 | ALDH1A1 (0.35) | MEN1KMT2AALDH1A1HTTCRHBP | |
| SCHEMBL6681638 | 0.74 | EPHX2 (0.52) | MEN1KMT2AALDH1A1GRIN2DGRIN3B | |
| SCHEMBL1238032 | 0.72 | ALDH1A1 (0.42) | MEN1KMT2AALDH1A1HTTCRHBP | |
| SCHEMBL9749719 | 0.71 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1HTTCRHBP | |
| SCHEMBL1552389 | 0.71 | MEN1 (0.63) | MEN1KMT2AALDH1A1HTTCRHBP | |
| Hydrochloric Acid SCHEMBL1238887 | 0.70 | LMNA (0.43) | MEN1KMT2AALDH1A1HTTCRHBP | |
| Hydrochloric Acid SCHEMBL7110958 | 0.70 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1HTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5680301 | 0.69 | LMNA (0.41) | ALDH1A1HTTCRHBPCRHR2MCOLN3 | |
| SCHEMBL8920876 | 0.67 | GRIN2D (0.38) | MEN1KMT2AALDH1A1SMN1; SMN2GRIN2D | |
| SCHEMBL1238812 | 0.67 | GLA (0.47) | KMT2AALDH1A1SMN1; SMN2ALOX12GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130354-A1 | 1-(Adamantyl) amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission | VERNALIS RESEARCH LIMITED | 2003-07-10 | — | — | US | disclosed |
| US-6500866-B1 | PROPHYLAXIS OF NEURODEGENERATIVE DISORDERS BY ADMINISTERING N-METHYL-D-ASPARTATE RECEPTOR ANTAGONIST OR PRODRUGS SUCH AS 3,5-DIMETHYL-1-ADAMANTANECARBOXIMIDAMIDE HYDROCHLORIDE | VERNALIS RESEARCH LIMITED (GB) | 2002-12-31 | — | — | US | disclosed |
| EP-1037874-B1 | 1-(ADAMANTYL)AMIDINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RES LTD (GB) | 2002-10-09 | — | — | EP | disclosed |
| EP-1037874-A1 | 1-(ADAMANTYL)AMIDINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999031051-A1 | 1-(ADAMANTYL)AMIDINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | CEREBRUS PHARMACEUTICALS LIMITED (GB) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130354-A1 | 1-(Adamantyl) amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission | SLC1A2, GRIN1, GRM1 | MEN1 751/4885KMT2A 2627/4885ALDH1A1 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.